The U.S. Food and Drug Administration says it is a constant balancing act to determine how much risk to consumers is acceptable in the drug approval process. No risk would result in few drugs coming to market. Some risk allows more. But Dr. Steve Galson, director of the FDA’s Center for Drug Evaluation and Research, tells PodTech’s Jason Lopez that the fate of drug companies — including startups that must get approval to stay in business — are not part of the Administration’s consideration. They spoke at Health Care Innovations 2006.
